These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 22747784)
21. Long-term graft outcome in patients with chronic allograft nephropathy after immunosuppression modifications. El-Agroudy AE; El-Dahshan KF; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA Clin Exp Nephrol; 2009 Feb; 13(1):66-72. PubMed ID: 18716711 [TBL] [Abstract][Full Text] [Related]
22. Effects of mycophenolate mofetil on renal interstitial fibrosis after Unilateral ureteral obstruction in rats. Zhang C; Zhu Z; Wang G; Deng A J Huazhong Univ Sci Technolog Med Sci; 2003; 23(3):269-70, 282. PubMed ID: 14526430 [TBL] [Abstract][Full Text] [Related]
23. Protective effects of atorvastatin on chronic allograft nephropathy in rats. Zhang W; Liu M; Wu Y; Zhu P; Yin C; Zhang W; Gu M J Surg Res; 2007 Dec; 143(2):428-36. PubMed ID: 17628598 [TBL] [Abstract][Full Text] [Related]
24. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644 [TBL] [Abstract][Full Text] [Related]
25. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts. Shimizu H; Takahashi M; Takeda S; Inoue S; Fujishiro J; Hakamata Y; Kaneko T; Murakami T; Takeyoshi I; Morishita Y; Kobayashi E Transpl Immunol; 2004 Nov; 13(3):219-27. PubMed ID: 15381205 [TBL] [Abstract][Full Text] [Related]
26. C4d deposition is correlated with the level of antivimentin antibody in rat kidneys undergoing chronic allograft nephropathy. Yang L; Lu YP; Luo GH; Song J; Tu ZD; Li YP Transplant Proc; 2008 Oct; 40(8):2786-9. PubMed ID: 18929862 [TBL] [Abstract][Full Text] [Related]
27. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
28. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Stoves J; Newstead CG; Baczkowski AJ; Owens G; Paraoan M; Hammad AQ Nephrol Dial Transplant; 2004 Aug; 19(8):2113-20. PubMed ID: 15161956 [TBL] [Abstract][Full Text] [Related]
29. Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model. He Z; Chen L; Qiu J; Li J; Zhao D; Chen G; Wang C J Int Med Res; 2009; 37(5):1396-410. PubMed ID: 19930844 [TBL] [Abstract][Full Text] [Related]
30. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456 [TBL] [Abstract][Full Text] [Related]
31. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Henne T; Latta K; Strehlau J; Pape L; Ehrich JH; Offner G Transplantation; 2003 Nov; 76(9):1326-30. PubMed ID: 14627911 [TBL] [Abstract][Full Text] [Related]
32. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Dharnidharka VR; Ho PL; Stablein DM; Harmon WE; Tejani AH Pediatr Transplant; 2002 Oct; 6(5):396-9. PubMed ID: 12390426 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of tacrolimus-induced chronic renal fibrosis following transplantation is regulated by ox-LDL and its receptor, LOX-1. Deng S; Jin T; Zhang L; Bu H; Zhang P Mol Med Rep; 2016 Nov; 14(5):4124-4134. PubMed ID: 27633115 [TBL] [Abstract][Full Text] [Related]
34. Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. Nakamura K; Oshima S; Maeda M; Morio H; Fukahori H; Nakanishi T; Tsujimoto S; Hirose J; Noto T; Hamakawa N; Inami M; Morokata T Int Immunopharmacol; 2018 Nov; 64():201-207. PubMed ID: 30195818 [TBL] [Abstract][Full Text] [Related]
35. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150 [TBL] [Abstract][Full Text] [Related]
36. CXC Chemokine Receptor Type 4 Antagonism Ameliorated Allograft Fibrosis in Rat Kidney Transplant Model. Zou XF; Gu JH; Cui ZL; Lu YW; Gu C Exp Clin Transplant; 2017 Aug; 15(4):448-452. PubMed ID: 28585910 [TBL] [Abstract][Full Text] [Related]
38. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
39. [The effects of mycophenolate mofetil on renal interstitial fibrosis and epithelial-myofibroblast translation in adenine-induced renal failure rats]. He CM; Zheng FL; Liu YP Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):901-5. PubMed ID: 19080229 [TBL] [Abstract][Full Text] [Related]
40. [Urinary connective tissue growth factor as a biomarker chronic allograft nephropathy in a rat model]. Luo GH; Sun ZL; Xia SJ Zhonghua Yi Xue Za Zhi; 2010 Jul; 90(28):1999-2003. PubMed ID: 20979869 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]